IMMUWIN, NCT04522544: Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC |
|
|
| Recruiting | 2 | 55 | Europe | Tremelimumab, Durvalumab, Y-90 SIRT, DEB-TACE | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca, Hannover Medical School | Hepatocellular Carcinoma Non-resectable, HCC | 03/25 | 09/25 | | |
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment |
|
|
| Completed | 2 | 22 | Europe | Cabozantinib | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen | Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | 12/24 | 12/24 | | |
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
|
|
| Recruiting | 2 | 125 | Europe | Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche | Lymphoma, Large B-Cell, Diffuse | 04/25 | 09/28 | | |
